Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.33+5.27 (+7.63%)
Close on Nov 19, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Inhibrx Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$125.73M. For fiscal 2025 it was -$135.03M. The highest annual figure on record is -$43.71M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$135.03M | – |
| FY2024 | Dec 31, 2024 | -$331.45M | – |
| FY2023 | Dec 31, 2023 | -$219.22M | – |
| FY2022 | Dec 31, 2022 | -$129.12M | – |
| FY2021 | Dec 31, 2021 | -$76.56M | – |
| FY2020 | Dec 31, 2020 | -$67.44M | – |
| FY2019 | Dec 31, 2019 | -$43.71M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$31.74M | – |
| Q2 FY2026 | Jun 30, 2026 | -$32.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.81M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$42.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$49.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$46.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$160.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$73.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$88.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$45.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$41.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$35.50M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$34.60M | – |
| Q1 FY2022 | Mar 31, 2022 | -$29.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.40M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.80M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.80M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.11M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.56M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.05M | – |
See a number that looks wrong?